Factors affecting the aldosterone/renin ratio

Hormone and Metabolic Research

Volumn 44, Issue 3, 2012, Pages 170-176

  Stowasser, M ^a   Ahmed, A H ^a   Pimenta, E ^a   Taylor, P J ^a   Gordon, R D ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

aldosterone; aldosterone renin ratio; assay; primary aldosteronism; renin; screening

Indexed keywords

ALDOSTERONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; DOXAZOSIN; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETONOGESTREL; HYDRALAZINE; METHYLDOPA; NONSTEROID ANTIINFLAMMATORY AGENT; PRAZOSIN; RENIN; SEROTONIN UPTAKE INHIBITOR; VERAPAMIL;

AGE DISTRIBUTION; BLOOD ANALYSIS; BODY POSTURE; FALSE POSITIVE RESULT; HUMAN; HYPOKALEMIA; KIDNEY FAILURE; LIQUID CHROMATOGRAPHY; LUTEAL PHASE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SALT INTAKE; SEX DIFFERENCE; TANDEM MASS SPECTROMETRY;

ALDOSTERONE; DIAGNOSTIC TESTS, ROUTINE; FEMALE; HUMANS; HYPERALDOSTERONISM; MALE; PREGNANCY; RENIN; SENSITIVITY AND SPECIFICITY;

EID: 84858006013     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0031-1295460     Document Type: Review

References (72)

1. Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, Nagata H, Izumiyama T. A screening test to identify aldosteroneproducing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med 1981; 141: 1589-1593 (Pubitemid 12234064)
2. Gordon R D, Klemm S A, Tunny T J, Stowasser M. Primary aldosteronism: Hypertension with a genetic basis. Lancet 1992; 340: 159-161
3. Gordon R D, Stowasser M, Tunny T J, Klemm S A, Rutherford J C. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994; 21: 315-318 (Pubitemid 24201225)
4. Loh K C, Koay E S, Khaw M C, Emmanuel S C, Young W F Jr. Prevalence of primary aldosteronism among asian hypertensive patients in singapore. J Clin Endocrinol Metab 2000; 85: 2854-2859 (Pubitemid 32269163)
5. Rossi G P, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello M J, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina A C, Mantero F. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48: 2293-2300 (Pubitemid 44873058)
6. Stowasser M, Gordon R D. Primary aldosteronism-careful investigation is essential and rewarding. Mol Cell Endocrinol 2004; 217: 33-39 (Pubitemid 38596626)
7. Young W F Jr. Primary aldosteronism: A common and curable form of hypertension. Cardiol Rev 1999; 7: 207-214 (Pubitemid 29316248)
8. Mulatero P, Stowasser M, Loh K C, Fardella C E, Gordon R D, Mosso L, Gomez-Sanchez C E, Veglio F, Young W F Jr. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from fi ve continents. J Clin Endocrinol Metab 2004; 89: 1045-1050 (Pubitemid 38368386)
9. Conn J W. The evolution of primary aldosteronism: 1954-1967. Harvey Lect 1966; 62: 257-291
10. Stowasser M, Gordon R D. The aldosterone-renin ratio for screening for primary aldosteronism. Endocrinologist 2004; 14: 267-276 (Pubitemid 39232121)
11. Tuck M L, Dluhy R G, Williams G H. Sequential responses of the reninangiotensin- aldosterone axis to acute postural change: Effect of dietary sodium. J Lab Clin Med 1975; 86: 754-763
12. Gordon R D. Primary aldosteronism. J Endocrinol Invest 1995; 18: 495-511
13. Nowaczynski W, Genest J, Kuchel O, Messerli F H, Guthrie G P Jr, Richardson K, Grose J. Age- and posture-related changes in plasma protein binding and metabolism of aldosterone in essential and secondary hypertension. J Lab Clin Med 1977; 90: 475-489 (Pubitemid 8183281)
14. Balikian H M, Brodie A H, Dale S L, Melby J C, Tait J F. Effect of posture on the metabolic clearance rate, plasma concentration and blood production rate of aldosterone in man. J Clin Endocrinol Metab 1968; 28: 1630-1640
15. Gordon R D, Gomez-Sanchez C E, Hamlet S M, Tunny T J, Klemm S A. Angiotensin- responsive aldosterone-producing adenoma masquerades as idiopathic hyperaldosteronism (iha: Adrenal hyperplasia) or lowrenin essential hypertension. J Hypertens Suppl 1987; 5: S103-S106 (Pubitemid 18074895)
16. Stowasser M, Gordon R D, Gunasekera T G, Cowley D C, Ward G, Archibald C, Smithers B M. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. J Hypertens 2003; 21: 2149-2157 (Pubitemid 38296877)
17. Espiner E A, Ross D G, Yandle T G, Richards A M, Hunt P J. Predicting surgically remedial primary aldosteronism: Role of adrenal scanning, posture testing, and adrenal vein sampling. J Clin Endocrinol Metab 2003; 88: 3637-3644 (Pubitemid 37034507)
18. Mulatero P, Bertello C, Rossato D, Mengozzi G, Milan A, Garrone C, Giraudo G, Passarino G, Garabello D, Verhovez A, Rabbia F, Veglio F. Roles of clinical criteria, computed tomography scan, and adrenal vein sampling in differential diagnosis of primary aldosteronism subtypes. J Clin Endocrinol Metab 2008; 93: 1366-1371
19. Gordon R D, Wolfe L K, Island D P, Liddle G W. A diurnal rhythm in plasma renin activity in man. J Clin Invest 1966; 45: 1587-1592
20. Gordon R D. The challenge of more robust and reproducible methodology in screening for primary aldosteronism. J Hypertens 2004; 22: 251-255 (Pubitemid 38250981)
21. Vagnucci A H, McDonald R H Jr, Drash A L, Wong A K. Intradiem changes of plasma aldosterone, cortisol, corticosterone and growth hormone in sodium restriction. J Clin Endocrinol Metab 1974; 38: 761-776
22. Kem D C, Weinberger M H, Gomez-Sanchez C, Kramer N J, Lerman R, Furuyama S, Nugent C A. Circadian rhythm of plasma aldosterone concentration in patients with primary aldosteronism. J Clin Invest 1973; 52: 2272-2277
23. Ney R L, Shimizu N, Nicholson W E, Island D P, Liddle G W. Correlation of plasma acth concentration with adrenocortical response in normal human subjects, surgical patients, and patients with cushing's disease. J Clin Invest 1963; 42: 1669-1677
24. Crane M G, Harris J J. Effect of aging on renin activity and aldosterone excretion. J Lab Clin Med 1976; 87: 947-959
25. Derkx F H, Steunkel C, Schalekamp M P, Visser W, Huisveld I H, Schalekamp M A. Immunoreactive renin, prorenin, and enzymatically active renin in plasma during pregnancy and in women taking oral contraceptives. J Clin Endocrinol Metab 1986; 63: 1008-1015 (Pubitemid 16004310)
26. Goldhaber S Z, Hennekens C H, Spark R F, Evans D A, Rosner B, Taylor J O, Kass E H. Plasma renin substrate, renin activity, and aldosterone levels in a sample of oral contraceptive users from a community survey. Am Heart J 1984; 107: 119-122 (Pubitemid 14219176)
27. Fischer M, Baessler A, Schunkert H. Renin angiotensin system and gender diff erences in the cardiovascular system. Cardiovasc Res 2002; 53: 672-677 (Pubitemid 34175260)
28. Oelkers W K. Effects of estrogens and progestogens on the reninaldosterone system and blood pressure. Steroids 1996; 61: 166-171 (Pubitemid 26146736)
29. Fommei E, Ghione S, Ripoli A, Maff ei S, Di Cecco P, Iervasi A, Turchi S. The ovarian cycle as a factor of variability in the laboratory screening for primary aldosteronism in women. J Hum Hypert 2009; 23: 130-135
30. Young W F. Primary aldosteronism: Renaissance of a syndrome. Clin Endocrinol 2007; 66: 607-618 (Pubitemid 46699525)
31. Pizzolo F, Raff aelli R, Memmo A, Chiecchi L, Pavan C, Guarini P, Guidi G C, Franchi M, Corrocher R, Olivieri O. Effects of female sex hormones and contraceptive pill on the diagnostic work-up for primary aldosteronism. J Hypertens 2010; 28: 135-142
32. Ahmed A H, Gordon R D, Taylor P J, Ward G, Pimenta E, Stowasser M. Are women more at risk of false-positive primary aldosteronism screening and unnecessary suppression testing than men? J Clin Endocrinol Metab 2011; 96: E340-E346
33. Montori V M, Schwartz G L, Chapman A B, Boerwinkle E, Turner S T. Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. Mayo Clin Proc 2001; 76: 877-882 (Pubitemid 32825908)
34. Stowasser M, Gordon R D, Rutherford J C, Nikwan N Z, Daunt N, Slater G J. Diagnosis and management of primary aldosteronism. J Renin Angiotensin Aldosterone Syst 2001; 2: 156-169 (Pubitemid 33685887)
35. Kerstens M N, Muller KA C, Volmer M, Koerts J, Sluiter W J, Dullaart R P. Reference values for aldosterone-renin ratios in normotensive individuals and effect of changes in dietary sodium consumption. Clin Chem 2011; 57: 1607-1611
36. Cain J P, Tuck M L, Williams G H, Dluhy R G, Rosenoff S H. The regulation of aldosterone secretion in primary aldosteronism. Am J Med 1972; 53: 627-637
37. Brown J J, Chinn R H, Davies D L, Fraser R, Lever A F, Rae R J, Robertson J I. Falsely high plasma potassium values in patients with hyperaldosteronism. Br Med J 1970; 2: 18-20
38. Don B R, Sebastian A, Cheitlin M, Christiansen M, Schambelan M. Pseudohyperkalemia caused by fi st clenching during phlebotomy. N Engl J Med 1990; 322: 1290-1292
39. Ahmed A H, Gordon R D, Taylor P, Ward G, Pimenta E, Stowasser M. Effect of atenolol on aldosterone/renin ratio calculated by both plasma renin activity and direct renin concentration in healthy male volunteers. J Clin Endocrinol Metab 2010; 95: 3201-3206
40. Gordon M S, Williams G H, Hollenberg N K. Renal and adrenal responsiveness to angiotensin ii: Infl uence of beta adrenergic blockade. Endocr Res 1992; 18: 115-131
41. Oparil S. Review of therapeutic modalities acting directly via central pathways. Clin Exp Hypertens A 1982; 4: 579-593 (Pubitemid 12025370)
42. Manhem P, Paalzow L, Hokfelt B. Plasma clonidine in relation to blood pressure, catecholamines, and renin activity during long-term treatment of hypertension. Clin Pharmacol Ther 1982; 31: 445-451 (Pubitemid 13097385)
43. Mitnick P D, Greenberg A, DeOreo P B, Weiner B M, Coff man T M, Walker B R, Agus Z S, Goldfarb S. Effects of two nonsteroidal anti-infl ammatory drugs, indomethacin and oxaprozin, on the kidney. Clin Pharmacol Ther 1980; 28: 680-689
44. Seifarth C, Trenkel S, Schobel H, Hahn E G, Hensen J. Infl uence of antihypertensive medication on aldosterone and renin concentration in the diff erential diagnosis of essential hypertension and primary aldosteronism. Clin Endocrinol (Oxf) 2002; 57: 457-465 (Pubitemid 35221345)
45. Young W F. Primary aldosteronism: Renaissance of a syndrome. Clin Endocrinol (Oxf) 2007; 66: 607-618 (Pubitemid 46699525)
46. Steingold K A, Matt D W, DeZiegler D, Sealey J E, Fratkin M, Reznikov S. Comparison of transdermal to oral estradiol administration on hormonal and hepatic parameters in women with premature ovarian failure. J Clin Endocrinol Metab 1991; 73: 275-280 (Pubitemid 21921869)
47. Ahmed A H, Gordon R D, Taylor P J, Ward G, Pimenta E, Stowasser M. Effect of contraceptives on aldosterone/renin ratio may vary according to the components of contraceptive, renin assay method, and possibly route of administration. J Clin Endocrinol Metab 2011; 96: 1797-1804
48. Young WF J. Primary aldosteronism: Update on diagnosis and treatment. Endocrinologist 1997; 7: 213-221
49. Brown M J, Hopper R V. Calcium-channel blockade can mask the diagnosis of conn's syndrome. Postgrad Med J 1999; 75: 235-236 (Pubitemid 29145871)
50. Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, Veglio F. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002; 40: 897-902 (Pubitemid 35434913)
51. Anderson G H Jr, Howland T, Domschek R, Streeten D H. Effect of sodium balance and calcium channel-blocking drugs on plasma aldosterone responses to infusion of angiotensin ii in normal subjects and patients with essential hypertension. J Clin Endocrinol Metab 1986; 63: 1126-1135 (Pubitemid 17173049)
52. Atkinson A B, Morton J J, Brown J J, Davies D L, Fraser R, Kelly P, Leckie B, Lever A F, Robertson J I. Captopril in clinical hypertension. Changes in components of renin-angiotensin system and in body composition in relation to fall in blood pressure with a note on measurement of angiotensin ii during converting enzyme inhibition. Br Heart J 1980; 44: 290-296 (Pubitemid 10020808)
53. Ahmed A H, Calvird M, Gordon R D, Taylor P J, Ward G, Pimenta E, Young R, Stowasser M. Effects of two selective serotonin reuptake inhibitor antidepressants, sertraline and escitalopram, on aldosterone/renin ratio in normotensive depressed male patients. J Clin Endocrinol Metab 2011; 96: 1039-1045
54. Campbell D J, Nussberger J, Stowasser M, Danser A H, Morganti A, Frandsen E, Ménard J. Activity assays and immunoassays for plasma renin and prorenin: Information provided and precautions necessary for accurate measurement. Clin Chem 2009; 55: 867-877
55. McKenna T J, Sequeira S J, Heffernan A, Chambers J, Cunningham S. Diagnosis under random conditions of all disorders of the reninangiotensin- aldosterone axis, including primary hyperaldosteronism. J Clin Endocrinol Metab 1991; 73: 952-957 (Pubitemid 21901130)
56. Gordon R D, Tunny T J. Aldosterone-producing-adenoma (a-p-a): Effect of pregnancy. Clin Exp Hypertens A 1982; 4: 1685-1693 (Pubitemid 13246192)
57. Stowasser M, Gordon R D, Klemm S A, Tunny T J. Renin-aldosterone response to dexamethasone in glucocorticoid-suppressible hyperaldosteronism is altered by coexistent renal artery stenosis. J Clin Endocrinol Metab 1993; 77: 800-804 (Pubitemid 23298670)
58. Beevers D G, Brown J J, Ferriss J B, Fraser R, Lever A F, Robertson J I, Tree M. Renal abnormalities and vascular complications in primary hyperaldosteronism. Evidence on tertiary hyperaldosteronism. Q J Med 1976; 45: 401-410
59. Kaplan N M. Primary aldosteronism with malignant hypertension. N Engl J Med 1963; 269: 1282-1286
60. Murphy B F, Whitworth J A, Kincaid-Smith P. Malignant hypertension due to an aldosterone producing adrenal adenoma. Clin Exp Hypertens A 1985; 7: 939-950 (Pubitemid 15005049)
61. Gordon R D, Geddes R A, Pawsey C G, O'Halloran M W. Hypertension and severe hyperkalaemia associated with suppression of renin and aldosterone and completely reversed by dietary sodium restriction. Australas Ann Med 1970; 19: 287-294
62. Warnock D G. Liddle syndrome: Genetics and mechanisms of na+ channel defects. Am J Med Sci 2001; 322: 302-307 (Pubitemid 33139183)
63. Palermo M, Quinkler M, Stewart P M. Apparent mineralocorticoid excess syndrome: An overview. Arq Bras Endocrinol Metabol 2004; 48: 687-696
64. Schirpenbach C, Seiler L, Maser-Gluth C, Beuschlein F, Reincke M, Bidlingmaier M. Automated chemiluminescence-immunoassay for aldosterone during dynamic testing: Comparison to radioimmunoassays with and without extraction steps. Clin Chem 2006; 52: 1749-1755 (Pubitemid 44330710)
65. Stowasser M, Gordon R D. Aldosterone assays: An urgent need for improvement. Clin Chem 2006; 52: 1640-1642 (Pubitemid 44330694)
66. Taylor P J, Cooper D P, Gordon R D, Stowasser M. Measurement of aldosterone in human plasma by semiautomated hplc-tandem mass spectrometry. Clin Chem 2009; 55: 1155-1162
67. Guo T, Taylor R L, Singh R J, Soldin S J. Simultaneous determination of 12 steroids by isotope dilution liquid chromatography-photospray ionization tandem mass spectrometry. Clin Chim Acta 2006; 372: 76-82 (Pubitemid 44286760)
68. Taylor P J, van RS P, Coombes J S, Gordon R D, Stowasser M. Simultaneous measurement of aldosterone and cortisol by high-performance liquid chromatography-tandem mass spectrometry: Application to dehydration-rehydration studies. J Chromat B 2010; 878: 1195-1198
69. Ferrari P, Shaw S G, Nicod J, Saner E, Nussberger J. Active renin versus plasma renin activity to defi ne aldosterone-to-renin ratio for primary aldosteronism. J Hypertens 2004; 22: 377-381 (Pubitemid 38250998)
70. Rutherford J C, Taylor W L, Stowasser M, Gordon R D. Success of surgery for primary aldosteronism judged by residual autonomous aldosterone production. World J Surg 1998; 22: 1243-1245 (Pubitemid 28514344)
71. Sukor N, Kogovsek C, Gordon R D, Robson D, Stowasser M. Improved quality of life, blood pressure, and biochemical status following laparoscopic adrenalectomy for unilateral primary aldosteronism. J Clin Endocrinol Metab 2010; 95: 1360-1364
72. Ahmed A H, Gordon R D, Pimenta E, Stowasser M. Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and/or amiloride, including a comparison with our previously published results in those with unilateral disease treated surgically. J Clin Endocrinol Metab 2011; 96: 2904-2911